IGF1R and melanoma: Arbiser and collaborators, while aiming to develop chemotherapeutic NPs to target receptors overexpressed in most advanced melanomas (IGF1R and CD44), prepared hyaluronic acid (HA) NPs for physical encapsulation of an active organopalladium compound (Pd1) [152].